BRAF-directed regimens linked to 22.3-month median OS in BRAF-mutant mCRC
Comparing Different Targeted Treatments for Patients with BRAF Mutant Colorectal Cancer
This reconstructed individual patient data meta-analysis pooled 18 randomized trials (11,931 patients) to compare targeted therapy classes i…
New data shows that treatments targeting the BRAF mutation offer a longer life expectancy than other targeted therapies.
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…